Details der Publikation - The effect of edelfosine on GRA1 and MIC3 expressions in acute toxoplasmosis

The effect of edelfosine on GRA1 and MIC3 expressions in acute toxoplasmosis

Abstract Phosphoinositide-dependent phospholipase-C (PI-PLC) triggers the calcium signaling pathway which plays an important role in dense granule and microneme secretion and pathogenesis of Toxoplasma gondii (T. gondii). There are limited data about the effects of phospholipid analogues against T. gondii. The current study assessed the effect of edelfosine, as a phospholipid analogue, on GRA1 and MIC3 expressions using in vitro and in vivo models of acute toxoplasmosis. Infected Vero cells were treated by edelfosine in two subgroups: 24 h following the cell infection and treatment at the same time of cell infection. Animal study was performed on forty mice in four groups including non-infected, infected untreated, infected edelfosine-treated, and infected pyrimethamine-treated. Gene and protein expression analyses were done using quantitative real-time PCR and western blot, respectively. Edelfosine significantly reduced the GRA1 (P < 0.01) and MIC3 (P < 0.01) mRNA and protein expressions in 24 h following the cell infection and at the same time of cell infection groups. In vivo study showed that the edelfosine significantly reduced the GRA1 expression in eye, and MIC3 expression in brain and liver. Moreover, the edelfosine-treated infected mice had significant higher survival rate compared with uninfected mice. The reducing effect of edelfosine on GRA1 and MIC3 mRNA and protein levels 24 h following the cell infection was more than treatment at the same time of cell infection group. Moreover, the effect of edelfosine on GRA1 and MIC3 expression in animal tissues was variable. These data showed that the edelfosine may decrease the T. gondii excretory/secretory antigens through inhibition of PI-PLC..

Medienart:	E-Artikel

Erscheinungsjahr:	2020
Erschienen:	2020

Enthalten in:	Zur Gesamtaufnahme - volume:119
Enthalten in:	Parasitology research - 119(2020), 4 vom: 22. Jan., Seite 1371-1380

Sprache:	Englisch

Beteiligte Personen:	Tanzifi, Asal [VerfasserIn] Khoshi, Amirhosein [VerfasserIn] Emami, Saeed [VerfasserIn] Sarvi, Shahabeddin [VerfasserIn] Sharif, Mehdi [VerfasserIn] Montazeri, Mahbobeh [VerfasserIn] Moghbeli, Meysam [VerfasserIn] Daryani, Ahmad [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.44$jParasitologie$XMedizin 42.00$jBiologie: Allgemeines
Themen:	Acute toxoplasmosis Edelfosine GRA1 MIC3 Phosphoinositide-dependent phospholipase C Toxoplasma gondii

RVK:	RVK Klassifikation ELIB24 ELIB09

Anmerkungen:	© Springer-Verlag GmbH Germany, part of Springer Nature 2020

doi:	10.1007/s00436-020-06601-x

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2117407811

Internformat


LEADER	01000naa a22002652 4500
001	OLC2117407811
003	DE-627
005	20230504133503.0
007	cr uuu---uuuuu
008	230504s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s00436-020-06601-x \|2 doi
035			\|a (DE-627)OLC2117407811
035			\|a (DE-He213)s00436-020-06601-x-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 590 \|a 610 \|q VZ
084			\|a ELIB24 \|q VZ \|2 rvk
084			\|a ELIB09 \|q VZ \|2 rvk
084			\|a 44.44$jParasitologie$XMedizin \|2 bkl
084			\|a 42.00$jBiologie: Allgemeines \|2 bkl
100	1		\|a Tanzifi, Asal \|e verfasserin \|4 aut
245	1	0	\|a The effect of edelfosine on GRA1 and MIC3 expressions in acute toxoplasmosis
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Springer-Verlag GmbH Germany, part of Springer Nature 2020
520			\|a Abstract Phosphoinositide-dependent phospholipase-C (PI-PLC) triggers the calcium signaling pathway which plays an important role in dense granule and microneme secretion and pathogenesis of Toxoplasma gondii (T. gondii). There are limited data about the effects of phospholipid analogues against T. gondii. The current study assessed the effect of edelfosine, as a phospholipid analogue, on GRA1 and MIC3 expressions using in vitro and in vivo models of acute toxoplasmosis. Infected Vero cells were treated by edelfosine in two subgroups: 24 h following the cell infection and treatment at the same time of cell infection. Animal study was performed on forty mice in four groups including non-infected, infected untreated, infected edelfosine-treated, and infected pyrimethamine-treated. Gene and protein expression analyses were done using quantitative real-time PCR and western blot, respectively. Edelfosine significantly reduced the GRA1 (P < 0.01) and MIC3 (P < 0.01) mRNA and protein expressions in 24 h following the cell infection and at the same time of cell infection groups. In vivo study showed that the edelfosine significantly reduced the GRA1 expression in eye, and MIC3 expression in brain and liver. Moreover, the edelfosine-treated infected mice had significant higher survival rate compared with uninfected mice. The reducing effect of edelfosine on GRA1 and MIC3 mRNA and protein levels 24 h following the cell infection was more than treatment at the same time of cell infection group. Moreover, the effect of edelfosine on GRA1 and MIC3 expression in animal tissues was variable. These data showed that the edelfosine may decrease the T. gondii excretory/secretory antigens through inhibition of PI-PLC.
650		4	\|a Toxoplasma gondii
650		4	\|a Acute toxoplasmosis
650		4	\|a Edelfosine
650		4	\|a GRA1
650		4	\|a MIC3
650		4	\|a Phosphoinositide-dependent phospholipase C
700	1		\|a Khoshi, Amirhosein \|4 aut
700	1		\|a Emami, Saeed \|4 aut
700	1		\|a Sarvi, Shahabeddin \|4 aut
700	1		\|a Sharif, Mehdi \|4 aut
700	1		\|a Montazeri, Mahbobeh \|4 aut
700	1		\|a Moghbeli, Meysam \|4 aut
700	1		\|a Daryani, Ahmad \|0 (orcid)0000-0003-0228-0803 \|4 aut
773	0	8	\|i Enthalten in \|t Parasitology research \|d Springer Berlin Heidelberg, 1928 \|g 119(2020), 4 vom: 22. Jan., Seite 1371-1380 \|h Online-Ressource \|w (DE-627)254638627 \|w (DE-600)1462976-8 \|w (DE-576)074531565 \|x 1432-1955 \|7 nnns
773	1	8	\|g volume:119 \|g year:2020 \|g number:4 \|g day:22 \|g month:01 \|g pages:1371-1380
856	4	0	\|u https://dx.doi.org/10.1007/s00436-020-06601-x \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_267
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2134
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	r	v	\|a ELIB24
936	r	v	\|a ELIB09
936	b	k	\|a 44.44$jParasitologie$XMedizin \|q VZ \|0 10640931X \|0 (DE-625)10640931X
936	b	k	\|a 42.00$jBiologie: Allgemeines \|q VZ \|0 106419943 \|0 (DE-625)106419943
951			\|a AR
952			\|d 119 \|j 2020 \|e 4 \|b 22 \|c 01 \|h 1371-1380

The effect of edelfosine on GRA1 and MIC3 expressions in acute toxoplasmosis

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände